Chronic pain’s highly crowded generics market makes gaining a strong foothold in the market challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug classes, including NSAIDs and opioid analgesics. The opioid analgesics class, a cornerstone of chronic pain treatment, is experiencing intense scrutiny from the public, payers, and prescribers; such scrutiny provides further opportunities for developers of less risk of abuse or deterrence agents, of safer and more tolerable analgesics, and of drugs with novel MOAs, such as biologic drugs targeting NGF. The emergence of agents with novel MOAs and the increase in prevalence of key subpopulations (e.g., osteoarthritic pain, chronic low back pain) will, in part, drive market growth.

QUESTIONS ANSWERED:

  • How do interviewed experts perceive the chronic pain therapy market to be changing given the emphasis on the risk of abuse/misuse with opioid analgesics?
  • How influential are abuse-deterrent formulations of extended-release/long-acting opioid analgesics on U.S. physicians’ prescribing for severe chronic pain?
  • What will be the impact of new analgesics from various drug classes, most notably the first-in-class anti-NGF biologic therapies, given their reputed robust efficacy counterbalanced with safety risks, on the highly genericized chronic pain market?
  • What are the greatest areas of unmet need in the treatment of chronic pain, and how are the emerging therapies expected to address these unmet needs?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading primary care physicians, pain specialists, and anesthesiologists. Supported by survey data collected for other DRG research.

Epidemiology: Prevalence, diagnosed, and drug treated rates of chronic pain subpopulations by country, specifically cancer pain, arthritic pain, chronic low back pain, fibromyalgia, and painful diabetic neuropathy; diagnosed prevalence of postherpetic neuralgia, by country.

Forecast: 5- and 10-year drug-level sales of key chronic pain therapies through 2028; forecast base-year segmentation by select chronic pain populations.

Emerging Therapies: Phase II: 25 drugs; Phase III/preregistration/registration: 8 drugs.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • September 2019
      • June 2019
      • February 2019
    • Executive Summary
      • Introduction
        • Key Findings
    • Market Outlook
      • Market Outlook
        • Key Findings
        • Expert Insight
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Chronic Pain?
        • What Factors Are Constraining the Market for Chronic Pain?
      • Drug-Class-Specific Trends
        • Antidepressants
        • Antiepileptic Drugs
        • NSAIDs
        • COX-2-Selective NSAIDs
        • Opioid Analgesics
        • Dual-Acting Opioid Analgesics
        • Subtype-Selective Sodium-Channel Antagonists
        • Cytokine Inhibitors
        • Anti-NGF Therapies
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Etiology
        • Conditions Causing Chronic Pain
      • Pathophysiology
        • Nociceptive Pain
        • Inflammatory Pain
        • Neuropathic Pain
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Introduction
        • Key Findings
        • Epidemiology Overview
      • Epidemiology Populations
        • Arthritic Pain
        • Cancer Pain
        • Chronic Low Back Pain
        • Fibromyalgia
        • Painful Diabetic Neuropathy
        • Postherpetic Neuralgia
        • Other Chronic Pain
        • Diagnosed and Drug-Treated Populations
    • Current Treatment Overview
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Antidepressants
        • Antiepileptic Drugs
        • NSAIDs
        • COX-2-Selective NSAIDs
        • Opioid Analgesics
        • Dual-Acting Opioid Analgesics
        • Opioid/NSAID or Acetaminophen Combinations
        • TRPV1 Receptor Agonists
        • Local Anesthetics
        • Cytokine Inhibitors
        • Viscosupplements
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Chronic Pain
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
        • Expert Insight
      • Pipeline Overview
      • Late-Phase Pipeline Analysis
        • Notable Developments in the Late-Phase Pipeline for Chronic Pain
      • Key Emerging Therapies
        • Antiepileptic Drugs
        • Subtype-Selective Sodium-Channel Antagonists
        • NSAIDs and COX-2 Selective NSAIDs
        • Opioid Analgesics
        • NMDA Receptor Modulators
        • Anti-NGF Therapies
        • Angiotensin II Receptor Antagonists
        • Cytokine Inhibitors
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Top-Down Forecasting Methodology
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • Assumptions Related to Market Segmentation
        • Assumptions Related to Physicians' Coding of Prescription Drugs for Pain
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Chronic Pain Bibliography

Author(s): Margaret M. Weigel; Andrea Witt, PhD; Bethany A. Kiernan, PhD; Lisa Cloonan, BA; Natalie Taylor, PhD

Margaret Weigel, is a Business Insights Analyst on the CNS/Ophthalmology Disorders team at Decision Resources Group. Her specialties are diabetic retinopathy/diabetic macular edema, postoperative pain, and multiple sclerosis; she has authored numerous primary and secondary market research products on these indications. Ms. Weigel obtained her from Washington and Lee University, where she studied psychology and conducted research in the neuroscience department, and her in pharmaceutical and healthcare business from the University of the Sciences in Philadelphia.

Andrea S. Witt, is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Decision Resources Group where she oversees a team of 14 Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.  Dr. Witt has been with Decision Resources Group for over 12 years, following CNS markets and trends. Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her degree.

Bethany A. Kiernan, is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders. Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her degree from Case Western Reserve University.

Lisa joined Decision Resources Group in 2015 as a business insights analyst for the Central Nervous System and Ophthalmology division. In this role, she analyzes the commercial opportunities for pharmacological therapies across the psychiatry space. Prior to joining Decision Resources Group, Lisa spent 6 years in clinical stroke research at Massachusetts General Hospital. While in the clinical research field, Lisa developed an expertise in neuroimaging analysis, as well as authored and co-authored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. Lisa holds bachelor of arts from Connecticut College, where her course work focused on behavioral neuroscience.

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.


Related Reports

Chronic Pain | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Fibromyalgia (US)

Fibromyalgia is a complex disease that is difficult to treat because of patient heterogeneity, frequent comorbid conditions, and numerous symptoms, including pain, depression, fatigue, and sleep...

View Details

Chronic Pain | Current Treatment | Detailed, Expanded Analysis (US)

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the ab...

View Details

Chronic Pain | Special Topics | Special Topics: How will Anti-NGF Therapies Disrupt Existing Pain Treatment Algorithms? (US)

The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanez...

View Details

Chronic Pain | Access & Reimbursement | Detailed, Expanded Analysis: Abuse-Deterrent Opioid Analgesics in Chronic Pain

Abuse-deterrent formulations (ADFs) of opioid analgesics entered the U.S. pain market in 2010 as an attempt to slow the increasing rates of abuse/...

View Details